Seroprevalence in Patients with Chronic Granulomatous Disease
Research type
Research Study
Full title
A Cross-Sectional, Observational Study of the Prevalence of Adenoviral-Specific Antibodies and Inflammatory Cytokines in Participants with Chronic Granulomatous Disease
IRAS ID
348455
Contact name
Claire Booth
Contact email
Sponsor organisation
Ensoma, Inc.
Clinicaltrials.gov Identifier
Duration of Study in the UK
0 years, 3 months, 11 days
Research summary
Chronic granulomatous disease (CGD) is a rare primary immune deficiency disorder. Approximately, it occurs with a frequency of 1 in 200,000 live births.
The purpose of this study, funded by Ensoma, Inc., is to analyse antibodies and cytokines circulating in the blood. Antibodies are proteins in the human blood that protect body from invaders such as viruses. Cytokines are chemical messengers that tell cells in the human body how to behave. The data collected in this study may help to design a potential clinical trial for the investigational therapy for the treatment of CGD in the future.
This is an observational study in male children and male adults with CGD. After obtaining informed consent, a blood sample will be collected from eligible participants during a routine on-site visit. A participant completes the study when the blood sample has been collected.The study is being run in the US and UK, including 2 study sites in the UK. It does not present any ethical, legal, or management issues.
REC name
London - Surrey Borders Research Ethics Committee
REC reference
24/PR/1263
Date of REC Opinion
28 Oct 2024
REC opinion
Further Information Favourable Opinion